ArticleEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2025
Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019.
Article in Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).
methodsThis is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).
resultsThe total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).
conclusionThe budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.